Our Ref: 361
May 2025

Doncaster and Bassetlaw Teaching Hospitals
NHS Foundation Trust

**Freedom of Information Act Request**

Under the Freedom of Information Act, I would like to request the following information:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel
- Atezolizumab
- Capivasertib
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Elacestrant
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab Monotherapy
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab
- Carboplatin + Paclitaxel + Pembrolizumab
- Pertuzumab (Perteja) + Trastuzumab (Herceptin)
- Phesgo (Pertuzumab + Trastuzumab in a single injection)
- Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
- Trastuzumab emtansine (Kadcyla)
- Any other active systemic anti-cancer therapy
- Aromatase Inhibitor as a single agent

I am writing to confirm that DBTH holds the information on the subject you have requested. However, I advise you that we will not be able to answer your request without exceeding the appropriate limit. This is because our pharmacy system doesn't store diagnosis data, so we're

unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

. Section 12 of the Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit, We have estimated that it would take more than 18 hours to carry out a manual search to locate, retrieve, and extract all the information you have requested. In this situation the associated cost would therefore exceed the appropriate fee limit of £450 set out under Freedom of Information & Data Protection (Appropriate Limit and Fees) Regulations 2007.

The fee limit specified in regulations for NHS trusts represents the cost of one person spending 2½ working days at a rate of £25 per hour determining whether the Trust holds the information sought and then locating, retrieving and extracting that information.

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Currently "Open" and "Closed to recruitment – in follow up" studies in breast cancer:

| **Title** | **Patients recruited at DBTH to date** |
|---|---|
| APPROACH RCT: an app for health & wellbeing after cancer – a randomised controlled trial | 57 |
| ATNEC–Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation who convert to node negative after NEoadjuvant Chemotherapy | 0 |
| The AUTONOMY study: Our ability to make decisions and have a say in the direction of our lives | 0 |
| Bridging the Age Gap in Breast Cancer: Improving Outcomes for Older Women | 73 |
| The MARECA study<br>National study of management of breast cancer locoregional recurrence and oncological outcome | 18 |
| SMALL: A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision | 8 |

| | |
|---|---|
| MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years and over: a randomised controlled trial | 33 |

If you are not satisfied with the handling of your request, you have the right to request an internal review. Requests for an internal review should be submitted within 40 working days from the date of this response, and should be addressed to d.wraith@nhs.net.

If you remain dissatisfied after the internal review, you have the right to appeal to the Information Commissioner's Office (ICO). The ICO can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
Website: https://ico.org.uk/make-a-complaint/